COVID-19 Vaccine Protection Against Infection Is Lower And S
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A study shows for the first time that people with cirrhosis who receive mRNA COVID-19 vaccination gain important protection against more serious outcomes like hospitalization and death. At the same time, however, the vaccines offer less protection against SARS-CoV-2 infection and take longer to take effect in this population.

Their study reveals that "being vaccinated is associated with a 65% efficacy after one dose and about 78% efficacy at reducing COVID infection after the second dose," said Dr. John, affiliate associate professor at the University of Miami Miller School of Medicine and chief of hepatology at the Bruce W. Carter VA Medical Center in Miami. "Patients with cirrhosis who are vaccinated might still get the infection, but they are unlikely to die or get hospitalized with COVID-19."

The researchers compared 20,037 people with cirrhosis nationwide who received at least one dose of either the Pfizer or Moderna mRNA vaccine at the Veterans Health Administration. They compared infections and outcomes in this group to another 20,037 matched patients with cirrhosis and similar COVID-19 risks who were not vaccinated.

Vaccines were administered between December 18, 2020, and March 17, 2021. Interestingly, more than 99% of participants who were eligible to get a second dose within the CDC recommended six weeks of the first dose did so. Another interesting finding was the timeline. There was no difference between the vaccinated and unvaccinated groups in the first 28 days after the first dose.

Vaccination was associated with 100% reduction in COVID-19 hospitalization and death after 28 days. No one died from COVID-19 in the vaccinated group compared to two deaths in the unvaccinated group, but a longer follow-up is needed to better study outcomes of death in this population.

Dr. T●●●●z H●●●●●●i and 1 others like this